Physician
Edmund J. Maclaughlin, MD, LLC
Edmund J. Maclaughlin, MD, LLC was paid $1.45M by Medicaid between Jan 2018 and Nov 2024, across 13 billing codes. Its largest line is Q5104, Injection, infliximab-abda, biosimilar, (renflexis), 10 mg — 30% of everything it billed.
33Billing provider infoEDMUND J. MACLAUGHLIN, MD, LLC
EASTON, MD 21601
EASTON, MD 21601
33aNPI1942492111assigned 08/13/2007
33bProvider typeRheumatology Physician
28Total paid$1.45M
24GClaims10,592
24DCodes billed13
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Rheumatology Physician providers in Maryland
Rank by total paid#1 of 19
Median peer was paid$76K
This provider vs. median19×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 185 | $18K | |
| 2019 | 199 | $15K | |
| 2020 | 753 | $76K | |
| 2021 | 1,450 | $129K | |
| 2022 | 2,216 | $397K | |
| 2023 | 3,592 | $604K | |
| 2024incomplete | 2,197 | $211K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | 30% | 201 | 188 | $442K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 28% | 4,706 | 3,794 | $399K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 22% | 2,216 | 1,634 | $316K |
| 96401 | 9.5% | 807 | 430 | $138K | |
| 96415 | 3.5% | 874 | 699 | $51K | |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 2.0% | 206 | 177 | $29K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.9% | 493 | 373 | $28K |
| 99244 | Office or other outpatient consultation, moderate to high complexity | 1.2% | 105 | 99 | $17K |
| J0897 | Injection, denosumab, 1 mg | 1.1% | 339 | 208 | $16K |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 451 | 351 | $10K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 157 | 121 | $3K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | <1% | 17 | 12 | $2K |
1 more codes
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 20 | $13.84 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMACLAUGHLIN, EDMUND (OWNER)